Strides Pharma Science

Strides Pharma Science Financial Debt Ratio

The Financial Debt Ratio of Strides Pharma Science (STAR.NS) as of Nov 22, 2026 is 31.07 %. In the previous year, Financial Debt Ratio was 43.10 % — a change of -27.90% (lower).

Financial Debt Ratio

31.07 %

YoY

-27.90%

Last updated:

Financial Debt Ratio of Strides Pharma Science is 2025 31.07 % . Financial Debt Ratio of Strides Pharma Science was 2024 43.10 % . It decreases by -27.90% lower compared to the previous year.

The Strides Pharma Science Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2018
37.56 INR
Jan 1, 2019
40.37 INR
Jan 1, 2020
36.33 INR
Jan 1, 2021
33.47 INR
Jan 1, 2022
43.36 INR
Jan 1, 2023
45.64 INR
Jan 1, 2024
43.10 INR
Jan 1, 2025
31.07 INR
The Strides Pharma Science Financial Debt Ratio history
YEARFinancial Debt RatioYoY
31.07 %-27.90%
43.10 %-5.56%
45.64 %+5.24%
43.36 %+29.54%
33.47 %-7.85%
36.33 %-10.02%
40.37 %+7.47%
37.56 %+2.52%
36.64 %-22.87%
47.50 %+34.31%
35.37 %+35.82%
26.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd. generates revenue through the development, manufacturing, and distribution of IP-led generics and bio-pharmaceutical products across its Pharmaceutical and Bio-pharmaceutical segments. The company serves global markets including Africa, Australia, Asia (excluding India), North America, Europe, India, and Others, offering niche pharmaceutical products in various dosage forms such as liquids, creams, ointments, soft gels, sachets, tablets, and modified release formats. Its manufacturing units in Bengaluru, Puducherry, Chennai, Singapore, Milan, Florida, and Nairobi produce anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drugs, alongside soft gelatin capsules. The firm's revenue streams are derived from the sale of its IP-led niche pharmaceutical products to healthcare providers, distributors, and global pharmaceutical companies operating in the specified geographical segments. Key product categories include anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, which are distributed through its global manufacturing network. The company's focus on specialized drug segments ensures consistent demand from healthcare systems and institutions managing infectious diseases. Strides Pharma Science Ltd. targets healthcare institutions, distributors, and pharmaceutical companies in regions such as North America, Europe, India, and Africa, where infectious disease management requires specialized treatments. Its manufacturing presence in multiple countries supports direct market access and cost efficiency, enabling the delivery of affordable pharmaceutical solutions. The company's product portfolio emphasizes high-demand therapeutic areas, aligning with global health priorities for infectious disease treatment. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

Financial Debt Ratio of Strides Pharma Science is 31.07 % in 2025.

Financial Debt Ratio of Strides Pharma Science changed from 43.10 % to 31.07 %, representing a -27.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Strides Pharma Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Strides Pharma Science

All Key Metrics — Strides Pharma Science